(Bloomberg) -- Novartis AG’s Sandoz family is poised to sell a roughly 1.2% stake in the Swiss pharmaceutical group.

FoRx Therapeutics appoints Dr. Jens Wurthner, PhD, as Chief Medical Officer and reports progress toward IND submission by mid ...

The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss ...

Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and ...

Since 2013, diagnoses of multiple sclerosis (MS) in Finland take less time after symptom onset and treatments follow the ...

Emasan AG is offering around 26.5M shares in Swiss Novartis (NVS) through Goldman Sachs, potentially raising $3B, Pablo Mayo Cerqueiro of ...

Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF95.00.

The site is expected to accelerate Amgen’s digital capabilities through artificial intelligence and data science to further ...

U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, CEO Robert ...

The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...